MX2022007968A - Dosificacion de gamma-hidroxibutirato (ghb). - Google Patents

Dosificacion de gamma-hidroxibutirato (ghb).

Info

Publication number
MX2022007968A
MX2022007968A MX2022007968A MX2022007968A MX2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A
Authority
MX
Mexico
Prior art keywords
ghb
hydroxybutyrate
dosing
gamma
narcolepsy
Prior art date
Application number
MX2022007968A
Other languages
English (en)
Spanish (es)
Inventor
Franck Skobieranda
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2022007968A publication Critical patent/MX2022007968A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
MX2022007968A 2019-12-24 2020-12-22 Dosificacion de gamma-hidroxibutirato (ghb). MX2022007968A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US202063052676P 2020-07-16 2020-07-16
PCT/US2020/066561 WO2021133778A1 (en) 2019-12-24 2020-12-22 Gamma-hydroxybutyrate (ghb) dosing

Publications (1)

Publication Number Publication Date
MX2022007968A true MX2022007968A (es) 2022-09-02

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007968A MX2022007968A (es) 2019-12-24 2020-12-22 Dosificacion de gamma-hidroxibutirato (ghb).

Country Status (14)

Country Link
US (3) US20210186907A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081204A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023508975A (cg-RX-API-DMAC7.html)
KR (1) KR20220119429A (cg-RX-API-DMAC7.html)
CN (1) CN115209885A (cg-RX-API-DMAC7.html)
AU (1) AU2020414694A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012594A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162974A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001743A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010330A2 (cg-RX-API-DMAC7.html)
IL (1) IL294176A (cg-RX-API-DMAC7.html)
MX (1) MX2022007968A (cg-RX-API-DMAC7.html)
TW (1) TW202135790A (cg-RX-API-DMAC7.html)
WO (1) WO2021133778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
AU2001291173A1 (en) 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
EP2566462B1 (en) * 2010-05-04 2020-07-08 Jazz Pharmaceuticals Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
CN115209885A (zh) 2022-10-18
WO2021133778A1 (en) 2021-07-01
BR112022012594A2 (pt) 2022-09-06
TW202135790A (zh) 2021-10-01
US20240285560A1 (en) 2024-08-29
CA3162974A1 (en) 2021-07-01
AU2020414694A1 (en) 2022-08-18
IL294176A (en) 2022-08-01
US20210186907A1 (en) 2021-06-24
US20210361601A1 (en) 2021-11-25
CO2022010330A2 (es) 2022-10-21
EP4081204A1 (en) 2022-11-02
JP2023508975A (ja) 2023-03-06
CL2022001743A1 (es) 2023-02-10
KR20220119429A (ko) 2022-08-29

Similar Documents

Publication Publication Date Title
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
PH12022551524A1 (en) Irak degraders and uses thereof
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
PH12021500030A1 (en) Il-2 conjugates and methods of use thereof
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
GEP20237506B (en) Pcsk9 antagonist compounds
PH12022551522A1 (en) Smarca degraders and uses thereof
PH12020551716A1 (en) Anti-ror antibody constructs
GEP20227443B (en) Magl inhibitors
MX2021015411A (es) Composiciones acopladoras especificas de macrofagos y metodos de uso de las mismas.
EA202190377A1 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
MX2025010681A (es) Formulaciones transdermicas
PE20210452A1 (es) Inhibidores de la arginasa
PH12022550130A1 (en) Enzyme inhibitors
PH12022550843A1 (en) Thienopyrimidones as trpa1 inhibitors
GEP20247585B (en) Furoindazole derivatives
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
ZA202001756B (en) Oral care compositions
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
PH12022551468A1 (en) Compounds active towards nuclear receptors
MX2022000811A (es) Inhibidores de enzimas.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2024012565A (es) Composiciones farmaceuticas de mosunetuzumab y metodos de uso
MX2020006905A (es) Composiciones farmaceuticas liquidas orales de aminosalicilatos.